FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns

[FDA]

Due to safety concerns, FDA is withdrawing its approval for the cancer medicine Ukoniq (umbralisib), which was approved to treat two specific types of lymphoma: marginal zone lymphoma (MZL) and follicular lymphoma (FL).


Baca selengkapnya di : http://www.fda.gov...